Long-term immunogenicity of hepatitis A virus vaccine in Alaska 17 years after initial childhood series.
Where this comes from
- Record sourced from PubMed, PMID 23204169.
- Also identified by DOI 10.1093/infdis/jis710 and PMC identifier 3611760.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The Centers for Disease Control and Prevention recommends hepatitis A virus (HAV) vaccination for all children at age 1 year and for high-risk adults. The vaccine is highly effective; however, protection duration is unknown. We report HAV antibody concentrations 17 years after childhood immunization, demonstrating that protective antibody levels remain and have stabilized over the past 7 years.
Medical subject headings
- Hepatitis A
- Hepatitis A Vaccines
- Hepatitis A virus